X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (101) 101
humans (100) 100
male (75) 75
female (72) 72
middle aged (69) 69
adult (59) 59
aged (50) 50
urology & nephrology (45) 45
life sciences (29) 29
retrospective studies (28) 28
glomerulonephritis (25) 25
treatment outcome (24) 24
rituximab (22) 22
abridged index medicus (19) 19
immunosuppressive agents - therapeutic use (18) 18
transplantation (18) 18
time factors (17) 17
vasculitis (17) 17
young adult (17) 17
aged, 80 and over (16) 16
immunology (16) 16
prognosis (16) 16
adolescent (15) 15
glomerular filtration rate (15) 15
biopsy (14) 14
kidney - pathology (14) 14
nephrology (14) 14
risk factors (14) 14
follow-up studies (13) 13
france (13) 13
disease (12) 12
kidney transplantation (12) 12
proteinuria (12) 12
chronic kidney disease (11) 11
medicine, general & internal (11) 11
drug therapy, combination (10) 10
kidney diseases (10) 10
rheumatology (10) 10
cyclophosphamide (9) 9
human health and pathology (9) 9
patients (9) 9
prospective studies (9) 9
renal failure (9) 9
research (9) 9
therapy (9) 9
disease progression (8) 8
focal segmental glomerulosclerosis (8) 8
france - epidemiology (8) 8
immunologic factors - therapeutic use (8) 8
kidney glomerulus - pathology (8) 8
prevalence (8) 8
wegeners-granulomatosis (8) 8
anca-associated vasculitis (7) 7
child (7) 7
complement (7) 7
glomerular-filtration-rate (7) 7
kidney - physiopathology (7) 7
lupus nephritis (7) 7
membranoproliferative glomerulonephritis (7) 7
mortality (7) 7
mutation (7) 7
nephritis (7) 7
nephropathy (7) 7
phenotype (7) 7
severity of illness index (7) 7
surgery (7) 7
survival (7) 7
anca (6) 6
anti-neutrophil cytoplasmic antibody-associated vasculitis - drug therapy (6) 6
antineutrophil cytoplasmic antibodies (6) 6
azathioprine (6) 6
child, preschool (6) 6
classification (6) 6
clinical research (6) 6
cohort studies (6) 6
creatinine (6) 6
cryoglobulinemia - complications (6) 6
cryoglobulinemia - drug therapy (6) 6
cyclophosphamide - therapeutic use (6) 6
dosage and administration (6) 6
drug therapy (6) 6
lupus nephritis - drug therapy (6) 6
management (6) 6
manifestations (6) 6
multidisciplinary sciences (6) 6
recurrence (6) 6
rituximab - therapeutic use (6) 6
acute kidney injury - etiology (5) 5
analysis (5) 5
antibodies, monoclonal, murine-derived - therapeutic use (5) 5
antibody-associated vasculitis (5) 5
autoantibodies (5) 5
azathioprine - therapeutic use (5) 5
biomarkers (5) 5
cardiac & cardiovascular systems (5) 5
care and treatment (5) 5
chi-square distribution (5) 5
chronic disease (5) 5
creatinine - blood (5) 5
cryoglobulin (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nephrologie et Thérapeutique, ISSN 1769-7255, 04/2018, Volume 14, Issue 2, pp. 118 - 126
Les cryoglobulines sont des immunoglobulines qui précipitent au froid. Elles se manifestent par une vascularite systémique associant purpura, arthralgies,... 
Cryoglobulin | Vasculitis | Membranoproliferative glomerulonephritis | Hépatite C | Cryoglobuline | Hepatitis C | Vascularite | Glomérulonéphrite membranoproliférative
Journal Article
Nephrologie et Therapeutique, ISSN 1769-7255, 04/2018, Volume 14, Issue 2, pp. 118 - 126
Cryoglobulins are immunoglobulins that undergo reversible precipitation at low temperatures. They can induce systemic vasculitis, characterized by purpuric... 
Cryoglobulin | Vasculitis | Membranoproliferative glomerulonephritis | Hepatitis C
Journal Article
La Revue du praticien, ISSN 0035-2640, 02/2018, Volume 68, Issue 2, p. 170
Acute interstital nephritis. Acute interstitial nephritis represents 10 to 30% of all biopsy-proven acute kidney injury cases. This disease is characterised by... 
Journal Article
JAMA, ISSN 0098-7484, 12/2017, Volume 318, Issue 21, pp. 2099 - 2110
Journal Article
Kidney International, ISSN 0085-2538, 03/2011, Volume 79, Issue 6, pp. 643 - 654
Journal Article
NEPHROLOGIE & THERAPEUTIQUE, ISSN 1769-7255, 04/2018, Volume 14, Issue 2, pp. 118 - 126
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2014, Volume 371, Issue 19, pp. 1771 - 1780
Journal Article
Nephrologie et Thérapeutique, ISSN 1769-7255, 04/2018, Volume 14, pp. S125 - S131
L’ifosfamide est un agent alkylant utilisé dans le cadre de chimiothérapies anticancéreuses, notamment dans la prise en charge de sarcomes. Sa néphrotoxicté a... 
Kidney failure | Ifosfamide | Syndrome de Fanconi | Tubulopathy | Tubulopathie | Fanconi syndrome | Insuffisance rénale
Journal Article
Nephrologie et Therapeutique, ISSN 1769-7255, 04/2018, Volume 14, pp. S125 - S131
Ifosfamide is a cytotoxic drug usually used in malignant sarcomas. The nephrotoxicity of this agent has been described essentially among children, revealed by... 
Kidney failure | Ifosfamide | Tubulopathy | Fanconi syndrome
Journal Article
Kidney International, ISSN 0085-2538, 08/2012, Volume 82, Issue 4, pp. 454 - 464
Dense deposit disease and glomerulonephritis with isolated C3 deposits are glomerulopathies characterized by deposits of C3 within or along the glomerular... 
complement | glomerulonephritis | clinical immunology | membranoproliferative glomerulonephritis (MPGN) | LONG-TERM | HEMOLYTIC-UREMIC SYNDROME | MESANGIOCAPILLARY GLOMERULONEPHRITIS | GLOMERULONEPHRITIS TYPE-II | MACULAR DEGENERATION | FACTOR-H DEFICIENCY | GLOMERULAR-FILTRATION-RATE | UROLOGY & NEPHROLOGY | MUTATIONS | MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS | MEMBRANE COFACTOR PROTEIN | Humans | Child, Preschool | Male | Complement System Proteins - metabolism | Young Adult | Time Factors | DNA Mutational Analysis | Renal Insufficiency - immunology | Child | Glomerulonephritis, Membranoproliferative - pathology | Genetic Predisposition to Disease | Risk Assessment | Complement C3 - metabolism | Gene Frequency | Risk Factors | Glomerulonephritis - genetics | Glomerulonephritis - immunology | Glomerulonephritis - mortality | Biomarkers - blood | Kidney Glomerulus - pathology | Disease Progression | Glomerulonephritis, Membranoproliferative - genetics | Glomerulonephritis, Membranoproliferative - immunology | Phenotype | Complement Factor H - metabolism | Glomerulonephritis, Membranoproliferative - mortality | Glomerulonephritis - pathology | Adolescent | Age of Onset | Membrane Cofactor Protein - genetics | Kidney Glomerulus - immunology | Mutation | Complement Factor I - metabolism | Haplotypes | Complement C3 Nephritic Factor - genetics | Glomerulonephritis - therapy | Infant | Case-Control Studies | Adult | Complement System Proteins - genetics | Female | Membrane Cofactor Protein - metabolism | Complement Pathway, Alternative - genetics | France | Renal Insufficiency - genetics | Kaplan-Meier Estimate | Complement Factor I - genetics | Treatment Outcome | Chi-Square Distribution | Glomerulonephritis, Membranoproliferative - therapy | Biopsy | Complement C3 Nephritic Factor - metabolism | Complement Factor H - genetics | Index Medicus
Journal Article
La Presse Medicale, ISSN 0755-4982, 03/2012, Volume 41, Issue 3, pp. 260 - 266
(20 to 50% of cases) (SLE). It significantly influences the functional prognosis and the patient survival. and the clinical presentation can be very... 
Journal Article
Presse Medicale, ISSN 0755-4982, 2012, Volume 41, Issue 3, pp. 260 - 266
Renal involvement is frequent (20 to 50% of cases) during the course of systemic lupus erythematosus (SLE). It significantly influences the functional... 
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 10/2017, Volume 76, Issue 10, pp. 1662 - 1668
ObjectivesA prospective randomised trial to compare two different durations of maintenance immunosuppressive therapy for the prevention of relapse in... 
RELAPSE | ANTIBODY-ASSOCIATED VASCULITIS | RISK-FACTORS | AZATHIOPRINE | PROTEINASE-3 | SYSTEMIC VASCULITIDES | INDUCTION | RHEUMATOLOGY | MAINTENANCE THERAPY | DAMAGE | RENAL SURVIVAL | Prednisolone - adverse effects | Azathioprine - administration & dosage | Prednisolone - administration & dosage | Prospective Studies | Humans | Middle Aged | Male | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - blood | Secondary Prevention - methods | Cyclophosphamide - therapeutic use | Maintenance Chemotherapy - adverse effects | Anti-Inflammatory Agents - adverse effects | Maintenance Chemotherapy - methods | Time Factors | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - complications | Adult | Anti-Inflammatory Agents - administration & dosage | Female | Immunosuppressive Agents - administration & dosage | Glomerular Filtration Rate | Survival Rate | Remission Induction | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Kidney Failure, Chronic - blood | Creatinine - blood | Immunosuppressive Agents - adverse effects | Aged | Azathioprine - adverse effects | Antibodies, Antineutrophil Cytoplasmic - blood | Kidney Failure, Chronic - etiology | Prevention | Complications and side effects | Autoantibodies | Vasculitis | Dosage and administration | Diagnosis | Risk factors | Creatinine | End-stage renal disease | Renal function | Rheumatology | Neutrophils | Antibodies | Arthritis | Survival | Immunosuppressive agents | Cyclophosphamide | Medical prognosis | Antineutrophil cytoplasmic antibodies | Remission | Kidney diseases | Azathioprine | Drug dosages | Prednisolone | Kidney transplantation | Index Medicus | Rheumatology and Autoimmunity | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Reumatologi och inflammation
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2013, Volume 111, Issue 2, pp. 265 - 272
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2011, Volume 365, Issue 25, pp. 2377 - 2388
The authors report that INF2 mutations are present in patients with focal segmental glomerulosclerosis (FSGS) associated with Charcot–Marie–Tooth neuropathy.... 
GLOMERULOSCLEROSIS | MEDICINE, GENERAL & INTERNAL | MYELIN | PROTEIN | NEUROPATHY | EPITHELIAL-CELLS | GENE | RHO | MEDIATED TRANSPORT | FORMIN | NEPHROPATHY | Humans | Middle Aged | Proteolipids - metabolism | Actins - metabolism | Male | Charcot-Marie-Tooth Disease - genetics | Young Adult | Kidney - metabolism | Glomerulosclerosis, Focal Segmental - etiology | Myelin and Lymphocyte-Associated Proteolipid Proteins | Adult | Female | Membrane Transport Proteins - metabolism | Microfilament Proteins - metabolism | Child | Microfilament Proteins - genetics | Charcot-Marie-Tooth Disease - complications | Schwann Cells - metabolism | Phenotype | Animals | Adolescent | Age of Onset | Heterozygote | Mice | Mutation | Myelin Proteins - metabolism | Glomerulonephritis | Gene mutations | Charcot-Marie-Tooth disease | Causes of | Genetic aspects | Research | Myelin proteins | Cdc42 protein | Disease | Exons | Genes | Amino acids | Nervous system | Neuropathy | Guanine nucleotide-binding protein | Proteins | Myelin P0 protein | Localization | Peripheral myelin protein 22 | Deoxyribonucleic acid--DNA | Kidneys | Schwann cells | Polymerization | Myelination | Genotyping | Biopsy | Glomerulus | Cytoskeleton | Genetic testing | Cytoplasm | Guanosinetriphosphatase | Index Medicus | Abridged Index Medicus | Schwann Cells | Genomics | Kidney | Charcot-Marie-Tooth Disease | Life Sciences | Proteolipids | Biochemistry, Molecular Biology | Actins | Microfilament Proteins | Membrane Transport Proteins | Myelin Proteins | Glomerulosclerosis, Focal Segmental
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 08/2018, Volume 77, Issue 8, pp. 1143 - 1150
ObjectiveTo compare individually tailored, based on trimestrial biological parameter monitoring, to fixed-schedule rituximab reinfusion for remission... 
granulomatosis with polyangiitis | ANCA vasculitis | ANCA | CD19+ B lymphocytes | microscopic polyangiitis | WEGENERS-GRANULOMATOSIS | B-CELLS | MAINTENANCE | RELAPSES | REFRACTORY GRANULOMATOSIS | SYSTEMIC VASCULITIS | DISEASE | ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES | RENAL INVOLVEMENT | INDUCTION | RHEUMATOLOGY | Recurrence | Antirheumatic Agents - administration & dosage | Humans | Middle Aged | Male | Drug Monitoring - methods | Rituximab - therapeutic use | Antirheumatic Agents - adverse effects | Adult | Female | Remission Induction - methods | Antirheumatic Agents - therapeutic use | Rituximab - adverse effects | Severity of Illness Index | B-Lymphocyte Subsets - drug effects | Drug Administration Schedule | Kaplan-Meier Estimate | Biomarkers - blood | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - drug therapy | Rituximab - administration & dosage | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis - immunology | Lymphocyte Count | Aged | Infusions, Intravenous | Precision Medicine - methods | Antibodies, Antineutrophil Cytoplasmic - blood | CD19 antigen | Rheumatology | Granulomatosis | Rituximab | Arthritis | Patients | Studies | Cyclophosphamide | Vasculitis | Dyspnea | Lymphocytes B | Medical prognosis | Antineutrophil cytoplasmic antibodies | Remission | Methotrexate | Cytoplasm | Life Sciences | Human health and pathology | Rhumatology and musculoskeletal system
Journal Article